Kernal Biologics
Financing Round
- Seed/Pre-A
Round Led by Symbiosis
KernalBio is a developer of mRNA therapies designed to develop curative immunotherapies for cancers and COVID-19. The company’s platform decreases immunogenicity of existing mRNA technologies and enables cell-specific therapeutic protein expression, thereby providing clinicians with more efficacious, tolerable, and affordable medicine for the global market.
View Website
Modality
- Genetic Medicine
Indication
- Oncology
Development Status
- Pre-Clinical